AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02885233 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist Control
Description: Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion.
Study NCT00574860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3285
Description: Oral rinse
Study NCT00574860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral rinse
Study NCT00574860 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: This will be the therapy most commonly used the the institution treating the patient
Study NCT01713595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline Aerosol
Description: A single 5ml dose of 7% Saline aerosol
Study NCT03933293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: 450mg, Q4W, subcutaneous injection
Study NCT03933293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins
Description: Lipid-lowering therapies
Study NCT03933293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statins
Description: Lipid-lowering therapies
Study NCT03933293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Lipid-lowering therapies
Study NCT03402945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: antibiotic
Study NCT03933293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Lipid-lowering therapies
Study NCT04181710 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Kidney transplant
Description: Organ preserved in preservation solution
Study NCT04181710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant
Description: Organ preserved in preservation solution
Study NCT03402945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: antibiotic
Study NCT03036826 — intervention group
Intervention type: DRUG
Intervention: Piperacillin/tazobactam
Description: antiinfective therapy with Piperacillin/Tazobactam within routine care
Study NCT03036826 — intervention group
Intervention type: DRUG
Intervention: Meropenem
Description: antiinfective therapy with Meropenem within routine care
Study NCT03402945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard wound dressing
Description: Any non-negative pressure wound dressing that is routinely used at study sites will be considered standard of care in the control arms.
Study NCT03764592 — intervention group
Intervention type: OTHER
Intervention: radiofrequency ablation
Description: Symptomatic patients whose substrates were identified will undergo catheter ablation; asymptomatic patients will be followed without undergoing catheter ablation.
Study NCT03397511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Baseline Interview, 2 Counseling Sessions at baseline and 2 weeks post baseline, and one follow up survey at one month
Study NCT00087074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00087074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT02423382 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Silicone oil removal
Description: The patients in each group will receive the same procedure of silicone oil removal.
Study NCT01617291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induced therapeutic hypothermia
Description: induced therapeutic hypothermia
Study NCT00271336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline
Study NCT00271336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Study NCT01469429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemoprevention
Description: Receive LBR lozenge PO
Study NCT01469429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemoprevention
Description: Receive LBR Saliva Substitute PO
Study NCT01469429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Receive Saliva Substitute placebo PO
Study NCT02159456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous enteral feeding via infusion pump
Study NCT02159456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent enteral feeding via gravity-based infusion
Study NCT01982266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRADION™ Hip Total Cartilage Replacement (TCR)™
Study NCT03857945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative mobility device(s) training
Description: Patients in Group 1 (the intervention, that is the mobility device training group group) will receive training on the mobility device(s) with the physical therapy visit during their standard pre-operative care.
Study NCT04241185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg of IV (intravenous) pembrolizumab once every 6 weeks.
Study NCT04241185 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional Radiotherapy (Bladder only)
Description: 64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.
Study NCT04241185 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Radiotherapy (Bladder only)
Description: 64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.
Study NCT04241185 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional Radiotherapy (Bladder and pelvic nodes)
Description: 64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.
Study NCT04241185 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Radiotherapy (Bladder and pelvic nodes)
Description: 64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.
Study NCT04241185 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy (Bladder only)
Description: 55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.
Study NCT04241185 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Hypofractionated Radiotherapy (Bladder only)
Description: 55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.
Study NCT04241185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
Study NCT04241185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
Study NCT04241185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
Study NCT04241185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorouracil (5-FU)
Description: 5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
Study NCT04241185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Description: MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
Study NCT04241185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitomycin C (MMC)
Description: MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
Study NCT04241185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
Study NCT04241185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
Study NCT04241185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Pembrolizumab
Description: Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.
Study NCT04445194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) low-dose group
Description: Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study NCT02158039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
Study NCT02158039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
Study NCT04445194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cells) high-dose group
Description: Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study NCT04445194 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant new coronavirus vaccine (CHO cells) placebo group
Description: Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study NCT00987155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergometry
Description: MetamaxII Cortex ergospirometry system (Cortex Biophysik GmbH, Germany). Arm cycling ergometer (Ergomed 840L, Siemens, GermanyMonark, Sweden), Electrically braked wheelchair ergometer (VP 100, Handisoft France)
Study NCT01777282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albiglutide
Description: Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
Study NCT00853450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6482
Description: Single intravenous infusion during a maximum of 5 hours
Study NCT01573741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
Study NCT00841165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Full face CPAP at 5cm H2O and 100% oxygen
Study NCT00853450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
Study NCT00853450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: 75 mg orally once daily during 7 days in each treatment arm
Study NCT00853450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: 75 mg orally once daily during 7 days in each treatment arm
Study NCT03971643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilobelimab
Description: IV infusions of vilobelimab diluted in sodium chloride.
Study NCT03333746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03333746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT00841165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-rebreather oxygen mask
Description: Oxygen administered through a non-rebreather mask
Study NCT02331771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.
Study NCT01777282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Study NCT01777282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biguanide
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Study NCT01777282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glinide
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Study NCT01777282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazolidinedione
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Study NCT01777282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-glucosidase inhibitor
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Study NCT01550237 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy daily verification reduced safety margins
Description: curative radiotherapy to 78 Gy in 39 fractions with daily CT position verification and reduced safety margins (7mm)
Study NCT01550237 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy weekly verification standard safety margins
Description: curative radiotherapy to 78 Gy in 39 fractions with weekly orthogonal position verification and standard safety margins (10-15 mm)
Study NCT02847260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remodulin
Description: Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.
Study NCT02331771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
Study NCT03333746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT01219816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Combination of chemotherapy + Epratuzumab
Study NCT01219816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Vincristine + Dexamethasone + Epratuzumab
Study NCT00443729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: raltegravir
Description: raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
Study NCT00443729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
Study NCT00443729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: lopinavir (+) ritonavir
Description: lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment
Study NCT00443729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: placebo
Description: raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
Study NCT00017810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The dietary intervention focused on diarrhea management using skill-building techniques that provided subjects with knowledge and a sense of confidence about making food choices.~Behavioral dietary intervention (Condition 1: treatment) - a low-fat, lactose-free, low insoluble fiber, high soluble fiber, and caffeine-free diet based on normal foods
Study NCT00017810 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Self-Care
Description: Standard information regarding self-care and healthy living with HIV - focused on healthy living with HIV and did not include dietary restrictions or dietary information that could affect bowel movements.
Study NCT03230578 — intervention group
Intervention type: OTHER
Intervention: Pharmacists & women's perspectives on pharmacist prescribed hormonal contraception
Description: The goal of this study is to identify the thoughts and perceptions of pharmacy access to hormonal contraception among rural women and pharmacists. This will be key in order to address concerns or perceived barriers in order to inform the implementation of this program.
Study NCT03642262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex®
Description: Mucinex® 600 mg single dose ER bi-layer tablet
Study NCT03642262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucinex®
Description: Mucinex® 600 mg single dose ER bi-layer tablet
Study NCT02420925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Celiac Plexus Block
Description: Patients will undergo celiac plexus block via upper endoscopy with endoscopic ultrasound guidance. Injections will be performed using 0.75% bupivicaine and 40mg/ml of triamcinolone, ideally 1ml each directly into the celiac ganglia. If no ganglia is identifiable, then the injection will be performed into the celiac space, located at the take off of the celiac artery from the aorta.
Study NCT04239755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100 MG Oral Tablet
Description: doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day
Study NCT04239755 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo in addition to the standard treatment.
Study NCT03802526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1805-R1
Description: 1 tablet, multiple oral dosing
Study NCT03802526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1805-R2
Description: 1 tablet, multiple oral dosing
Study NCT03802526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1805-R1 and NVP-1805-R2
Description: NVP-1805-R1,1 tablet and NVP-1805-R2, 1 tablet, co-administration, multiple oral dosing
Study NCT02298127 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Auricular acupressure
Description: For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.
Study NCT02298127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.
Study NCT03792945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local injection
Description: In addition to the local injection, carpal tunnel brace will be given.
Study NCT03792945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shock wave therapy
Description: In addition to all ESWT participants, carpal tunnel brace will be given.
Study NCT01317771 — intervention group
Intervention type: PROCEDURE
Intervention: Open proximal biceps tendon tenodesis with an EndoButton
Description: Surgical fixation for bicipital pathology
Study NCT03333746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02510157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: active comparator
Study NCT02510157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: placebo controlled intervention
Study NCT02510157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery